drugset / Trial / NCT06356311
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
RandomizedParallel-groupSingle-blindTreatment
Summary
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).
Timeline
- Start
- 2024-05-03
- Primary completion
- 2027-01-04
- Completion
- 2027-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Comparator | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |
| Comparator | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 4 mg/kg | Intravenous |
| Comparator | TAS-102 | Small molecule | 35 mg/m2 | Oral |
| Background | Acetaminophen | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | Topical |
| Background | Nystatin | Unknown | — | Oral |